Does ruxolitinib prolong the survival of patients with myelofibrosis?

Blood. 2017 Feb 16;129(7):832-837. doi: 10.1182/blood-2016-11-731604. Epub 2016 Dec 28.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Case-Control Studies
  • Clinical Trials, Phase III as Topic
  • Evidence-Based Practice
  • Humans
  • Janus Kinase Inhibitors / therapeutic use
  • Male
  • Nitriles
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / mortality
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • Randomized Controlled Trials as Topic
  • Splenomegaly / drug therapy
  • Survival Analysis
  • Treatment Outcome

Substances

  • Janus Kinase Inhibitors
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib